Rigel Pharmaceuticals | RIGL - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Agenus USD 6.21M 4.34M 2026-03
Amgen USD 1.68B 40M 2026-09
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 4.07B 1.73B 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Celldex Therapeutics USD 14.84M 1.74M 2026-09
Daiichi Sankyo JPY 237.75B 12.21B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 72.62M 43.49M 2026-09
MacroGenics USD 7.9M 1.81M 2026-06
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Pfizer USD 3.28B 132M 2026-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Veracyte USD 57.95M 2.25M 2026-09